Pricing And Fewer Treatments Eat At Biogen Biosimilar Sales
US-Based Firm Looking Beyond EU And Samsung Bioepis Partnership
Samsung Bioepis saw sales of its anti-TNF biosimilars in Europe drop in the first quarter of this year, though the traditionally innovative Biogen continues to look to new products and geographies to build its biosimilars presence.
